Synovial sarcoma a DNA flow cytometric study

El‐Naggar, Adel K.; Ayala, Alberto G.; Abdul‐Karim, Fadi W.; McLemore, Donia; Ballance, William A.; Garnsey, Lisa; Ro, Jae Y.; Batsakis, John G.

doi:10.1002/1097-0142(19900515)65:10<2295::aid-cncr2820651022>3.0.co;2-7

Cited by 74 publications

(32 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our case also, keeping in view the extensive morbidity of surgery, chemoradiation was the treatment resorted to. There are reports in literature, which support the chemotherapy as successful mode of treatment [14,15]. Besides having some radiation mucositis the patient is doing fi ne after ten months of treatment.…”

Section: Discussionmentioning

confidence: 89%

Synovial sarcoma of unusual site treated with chemo-radiation

Anand¹,

Kumar²,

Chaudhary³

et al. 2008

Indian J Otolaryngol Head Neck S

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 89%

Synovial sarcoma of unusual site treated with chemo-radiation

Anand¹,

Kumar²,

Chaudhary³

et al. 2008

Indian J Otolaryngol Head Neck S

View full text Add to dashboard Cite

“…SS consistently bears a t(X;18) chromosomal translocation, which produces 1 of 3 possible fusion oncogenes: SS18-SSX1, SS18-SSX2, or SS18-SSX4 (2). No additional consistent genomic perturbations have been identified by profiling, suggesting that the fusion oncogene can drive transformation independently (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Paracrine osteoprotegerin and β-catenin stabilization support synovial sarcomagenesis in periosteal cells

Barrott¹,

Illum²,

Jin³

et al. 2017

Journal of Clinical Investigation

View full text Add to dashboard Cite

were performed using a 2-tailed Student's t test, with a P value of less than 0.05 considered significant.Study approval. All mouse experiments were conducted with the approval of the IACUC of the University of Utah and in accordance with international legal and ethical standards. Clinical analyses were performed with approval from the IRB of the University of Utah and in accordance with legal and ethical standards. As only extant records were reviewed, the requirement for consent was waived by the IRB. Author contributionsKBJ and MLH conceived the experiments. JJB, BEI, HJ, MLH, YW, MH and KBJ performed experiments. JJB, AG, and KBJ analyzed data. MRC contributed mice and resources. KBJ wrote the manuscript, and all authors edited it.

show abstract

“…Many studies have attempted to identify molecular markers of prognostic significance. It has been shown that the over-expression of cell cycle regulatory proteins p53, proliferation markers (PCNA, Ki-67), and aneuploid DNA content are associated with reduced survival of patients with synovial sarcomas [4,5,6,7,8,9,10,11]. To our knowledge, the role of other molecular markers, such as epidermal growth factor receptor (EGFR) and Her2/neu (c-erbB-2), has been previously evaluated only in heterogeneous groups of soft tissue tumors that included very limited numbers of synovial sarcomas [12,13,14].…”

Section: Introductionmentioning

confidence: 99%